PolyActiva Strengthens Executive Team to Accelerate U.S. Expansion and Advance Late-Stage Clinical Development of Sustained-Release Ocular Therapies PolyActiva, a clinical-stage biopharmaceutical company at the forefront of innovation in ocular drug delivery, has announced two key leadership appointments that signal a…
Tempus Secures FDA 510(k) Clearance for AI-Driven ECG-Low EF Software, Expanding Capabilities in Cardiovascular Risk Detection Tempus AI, Inc. (NASDAQ: TEM), a trailblazer in applying artificial intelligence to drive precision medicine forward, has reached a significant milestone in the cardiology…
Veranex Launches Industry’s First Innovation CRO to Accelerate MedTech R&D in a Tight Capital Climate Veranex, a global leader in integrated product development and contract research services for medical technology, has officially launched the industry’s first Innovation CRO (iCRO) —…
C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative plasma-based assays designed for Research Use Only, expanding its suite…
Enveric Biosciences’ Lead Candidate EB-003 Shows Promising Preclinical Efficacy in PTSD Model, Signaling a Potential Breakthrough in Neuroplasticity-Based Psychiatric Treatment Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company advancing a new class of neuroplastogenic small molecules, has announced promising new…
EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered prominent recognition across two of the ophthalmology industry’s most respected…
Acadia Pharmaceuticals Unveils Ambitious Growth Strategy, Eyes $12 Billion Pipeline with Female-Led R&D Powerhouse More than three decades after its founding in 1993, Acadia Pharmaceuticals is embracing a bold new chapter, unveiling what it calls a biotech transformation under the…
Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development pipeline, revealing that its investigational oral therapy oveporexton (TAK-861) has…
ICON Celebrated for Clinical Research Leadership, Innovation, and Sustainability in 2025 a global leader in healthcare intelligence and clinical research, has received widespread industry recognition during the first half of 2025. The company has been honored with multiple awards acknowledging…
Gamma Delta T Cell Therapy: A Transformative Frontier in Cancer Immunotherapy with U.S. and China Leading Global Trials Gamma delta (γδ) T cell therapy is rapidly emerging as a promising frontier in the field of cancer immunotherapy. Unlike the more…
Manitoba Bioscience Association Backs Government Plan to Boost Research and Clinical Trials Bioscience Association Manitoba (BAM) has voiced strong support for a major new initiative from the Manitoba government aimed at advancing health research and clinical trials across the province.…
Health Secretary Robert F. Kennedy Jr. Endorses Broader RSV Vaccine Use, Following Guidance from Former ACIP Panel Despite ousting the Centers for Disease Control and Prevention’s (CDC) vaccine advisory panel last month, Health and Human Services (HHS) Secretary Robert F.…